Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

0
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Impact Index Per Article
Citation(s) in RCA

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Category

Show more Refine

For: Shimomura A, Horiike A, Tambo Y, Ohyanagi F, Yanagitani N, Kitazono S, Fujiwara Y, Tanabe Y, Ohkubo S, Yamamoto N, Nishio M. Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-b87] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

For:	Shimomura A, Horiike A, Tambo Y, Ohyanagi F, Yanagitani N, Kitazono S, Fujiwara Y, Tanabe Y, Ohkubo S, Yamamoto N, Nishio M. Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-b87] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

No articles found.

(The first 100,000 artilces are displayed in RCA.)